WELBIO strategic plan adopted by the Governing board. The plan is articulated towards an ambition vision of WELBIO increasing its capacity to offer a stable and stimulating framework for the best junior and advanced investigators, and to maximise the impact of their research activities for the socioeconomic development of Wallonia.
The team of Prof Decio L. Eizirik, WELBIO researcher and director of the ULB Center for Diabetes Research, ), in collaboration with Inserm researchers (CNRS/Nice Sophia Antipolis University) and colleagues from Germany and Denmark, have shown that GABA, a neurotransmitter that is sometimes used as a dietary supplement, can induce the regeneration of insulin-producing cells. Their article has recently been published in Cell.
The team of Prof. Patrice D. Cani, WELBIO researcher at the Louvain Drug Research Institute of the University of Louvain (UCL, Belgium), has published their recent findings in the prestigious scientific journal Nature Medicine.
In a new study published in Cell Stem Cell, researchers lead by Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Interdisciplinary Research Institute (IRIBHM), Université libre de Bruxelles, Belgium, demonstrated for the first time, that the cancer cell of origin controls EMT in skin squamous cell carcinoma, the second most frequent skin cancer.
In a review article published in Nature Microbiology, the team of Yves Dufrêne, WELBIO investigator at UCL, together with a team from the Johns Hopkins School of Medicine, discuss recent progress in live cell nanoscopy, an exciting new research field that was awarded the Nobel prize in Chemistry 2014.
In a study published in The Journal of Experimental Medicine, the group of Pierre Close and Alain Chariot, WELBIO Investigator at ULg, shows that ELP3 plays a key role during breast cancer progression.
Researchers of the de Duve Institute (Université Catholique de Louvain) have discovered how a broad variety of tumor cells block the function of human CD8 T cells, the killer cells of our immune system, by coating them with a protein that could be compared to some molecular glue. The WELBIO-funded study, which was led by Anne-Elisabeth Petit and Pierre van der Bruggen of the de Duve Institute and the Brussels Branch of the Ludwig Institute for Cancer Research, details how this glue—a naturally occurring protein named galectin—stops activated T cells that are primed and ready to kill cancer cells from triggering their attack.
In a recent article published in Nature Chemical Biology, the laboratories of Emile Van Schaftingen (WELBIO investigator at UCL) and Guido Bommer report the discovery of a highly conserved metabolite repair enzyme needed for the proper functioning of two major metabolic pathways, glycolysis and the pentose phosphate pathway.
In an article published in The Journal of Clinical Investigation, researchers at the University of Liege, co-directed by Fabrice Bureau, WELBIO investigator, have, for the first time, identified the existence of a sub–group of eosinophils called resident eosinophils which are present in the lungs of healthy individuals and which, unlike inflammatory eosinophils, play a regulatory and protective role while maintaining the balance of the immune system and preventing it from responding in an abnormal way such as observed during an asthma attack. The discovery of these specific eosinophils offers promising therapeutic and prophylactic opportunities for the treatment and prevention of asthma.
WELBIO is pleased to announce a “Bridge grant” has been awarded to Professor Pierre van der Bruggen, Principal Investigator at the de Duve Institute (Université Catholoque de Louvain). The WELBIO Bridge fund is intended for WELBIO investigators and designed to bridge the gap between early stage research and the valorisation of the research findings (patent application, technology transfer, applied research project).
In a study published in Nature, researchers led by Pr. Cédric Blanpain, MD/PhD, WELBIO investigator, and Professor at the Université Libre de Bruxelles, in collaboration with Pr. Benjamin D Simons, University of Cambridge,UK, demonstrated that the capacity of oncogene-expressing cells to induce tumor formation depends on the clonal dynamics of the cancer cell of origin.
Twenty-two WELBIO research programmes are currently supported through the Fund for Strategic Fundamental Research (F.R.S. (Fonds de la Recherche Scientifique) [Fund for Scientific Research]-FNRS), within three universities of the Wallonia-Brussels Federation. The WELBIO researchers conduct innovative research in various areas such as cancer biology, neurobiology, immunology, genetics, development biology, metabolism or microbiology. Their scientific discoveries may lead to the development of new medicines, treatments or diagnoses (e.g. cancer, neuropsychiatric, metabolic or inflammatory diseases, neurodegenerative disorders, antibiotic resistance) as well as to biotechnology applications.
In a study that makes the cover of the current issue of Genes & Development, researchers from the ULB Cancer Research Center, U-CRC, led by Cédric Blanpain, MD/PhD, WELBIO investigator and Professor at the Faculty of Medicine, Université libre de Bruxelles, developed new methods to assess with great precision the multipotent or unipotent fate of mammary gland and prostate stem cells.
In a recent paper published in Nature Communications, the laboratories of Guido Bommer and Emile Van Schaftingen (WELBIO investigator) at the Université catholique de Louvain (UCL), describe a new post-translational modification, which is deficient in three genetic diseases affecting skeletal muscle and the CNS.
WELBIO is pleased to announce a "Bridge grant" has been awarded to Dr Roger, Principal Investigator at the « Institut de Recherche en Biologie Humaine et Moléculaire » (Université Libre de Bruxelles). The WELBIO Bridge fund is intended for WELBIO investigators and designed to bridge the gap between early stage research and the valorisation of the research findings (patent application, technology transfer, applied research project).
Patrice Cani, WELBIO investigator at UCL, is the first French-speaking Belgian scientist to receive an ERC (European Research Council) Proof of Concept grant. ERC Proof of Concept Grants are designed to support ERC grantees with the commercial or societal application of the results of their funded research.
In a study published in Cancer Research, the group of Alain Chariot, Investigator WELBIO at ULg, describes the role of kinase IKKepsilon in the development of intestinal tumors.
In a study published in Nature communications, the group of André Goffinet, Investigator at UCL, shows that immature neurons regulate the fate of apical progenitors through Wnt7–Celsr3–Fzd3 signalling.
WELBIO is pleased to announce a “Bridge grant” has been awarded to Professor Coulie, Principal Investigator at the de Duve Institute (Université Catholoque de Louvain). The WELBIO Bridge fund is intended for WELBIO investigators and designed to bridge the gap between early stage research and the valorisation of the research findings (patent application, technology transfer, applied research project).
In a paper published in Nano Letters, the team of Yves Dufrêne, WELBIO Investigator at UCL, together with chemists from the Namur University, demonstrate how the tools of nanotechnology (nanoscopy, nanoparticles) can help fighting bacterial infections, thereby complementing antibiotherapy.
In a paper published in the Proceedings of the National Academy of Sciences USA (PNAS), the team of Yves Dufrêne, WELBIO Investigator at UCL, sheds new light into the role of SasG in mediating the formation of staphylococcal biofilms.
In a new study that makes the cover of the January issue of Cell Reports, researchers led by Pr. Cédric Blanpain, WELBIO investigator at ULB uncovered the number and mode of growth of the earliest cardiac progenitors during mouse heart morphogenesis.